SEI Investments
GLUE icon

SEI Investments’s Monte Rosa Therapeutics GLUE Stock Holding History

SEI Investments’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.28M Buy
77,681
+18,013
+30% +$344K ﹤0.01% 2230
2025
Q4 		$936K Buy
59,668
+43,262
+264% +$583K ﹤0.01% 2213
2025
Q3 		$122K Hold
16,406
– – ﹤0.01% 2694
2025
Q2 		$74K Sell
16,406
-935
-5% -$4.17K ﹤0.01% 2720
2025
Q1 		$80.5K Buy
17,341
+105
+0.6% +$644 ﹤0.01% 2635
2024
Q4 		$120K Buy
+17,236
New +$129K ﹤0.01% 2553

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

SEI Investments's GLUE Position: Q1 2026 in Review

SEI Investments increased its Monte Rosa Therapeutics (GLUE) stake by 30% in Q1 2026, buying an estimated $344K and bringing the position to 77,681 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2230.

SEI Investments first reported a position in GLUE in Q4 2024 and has held it in 6 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • SEI Investments held 77,681 shares of Monte Rosa Therapeutics worth $1.28M as of Q1 2026.
  • SEI Investments bought 18,013 Monte Rosa Therapeutics shares in Q1 2026, an estimated $344K.
  • Monte Rosa Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q1 2026, its #2230 holding.
  • SEI Investments first reported a position in Monte Rosa Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on SEI Investments's 13F filing for Q1 2026, filed 13 May 2026.